Eloralintide

Why selectivity matters. Amylin signals through receptor complexes formed when the calcitonin receptor associates with receptor activity-modifying proteins. Earlier amylin analogues, including pramlintide and to a degree cagrilintide, engage the calcitonin receptor as well. Eloralintide was designed to be selective for the amylin receptors, and the discovery-to-proof-of-concept paper traces that engineering through in vitro selectivity assays to the first human data [2][3].

The phase 2 result. 263 adults across 46 US research centres, with a mean baseline weight of 109.1 kg and BMI of 39.1, were randomised to placebo or one of six eloralintide regimens for 48 weeks. Mean weight change was -9% at 1 mg, -12% at 3 mg, -18% at 6 mg and -20% at 9 mg, against -0.4% on placebo. The 6-9 mg escalation also reached -20%; the 3-9 mg escalation reached -16% [1].

Twenty percent on a single mechanism that does not touch the GLP-1 receptor is the headline. Semaglutide 2.4 mg gives about 15% over 68 weeks [4]; CagriSema, which combines semaglutide with an amylin analogue, gives 20.4% [5]. Eloralintide alone reached that in 48 weeks.

The side-effect signature is its own. Nausea ran 11% at 1 mg, 13% at 3 mg, 64% at 6 mg, 33% at 9 mg, 54% at 6-9 mg and 25% at 3-9 mg, against 14% on placebo - notably not monotonic in dose, which points to escalation schedule rather than exposure as the driver. Fatigue was the other prominent effect, at 0%, 13%, 29%, 43%, 46% and 21% against 12% on placebo [1]. Fatigue at that rate is not a typical incretin finding and is worth watching.

What does not exist. No phase 3. No cardiovascular outcome data. No exposure beyond 48 weeks. No trial outside the United States. No published data in type 2 diabetes - the phase 2 trial excluded it. The cardiovascular implications of the mechanism have been reviewed [6] and network meta-analyses have started placing the amylin agents against each other [7], but review articles are not evidence of outcomes.

Amylin is co-secreted with insulin after a meal and produces satiation through amylin receptors in the area postrema and nucleus tractus solitarius - brainstem regions that sit outside the blood-brain barrier and sample circulating signals directly. The pathway is distinct from GLP-1's, which is the entire strategic point: two independent satiety signals should add rather than saturate [8][9].

The amylin receptors are heterodimers of the calcitonin receptor with receptor activity-modifying proteins 1, 2 or 3. That shared calcitonin receptor core is what makes selectivity hard, and achieving it is what eloralintide's discovery programme was for [2]. Whether selectivity translates into a better clinical profile than cagrilintide's is not something the existing trials can answer - the two have never been compared.

The fatigue signal is the most mechanistically interesting adverse effect. It is dose-related, it was absent at the lowest dose and reached 43-46% at the highest, and it is not a prominent feature of incretin therapy. Nothing in the published work explains it.

A once-weekly subcutaneous injection. The discovery paper describes the translational work from in vitro receptor assays through to clinical proof of concept [2]; no formulation details beyond subcutaneous weekly dosing have been published.

Only 48 weeks of phase 2 data in 263 people exist, which frames everything below.

Nausea peaked at 64% in the 6 mg group and was 33% at 9 mg, against 14% on placebo - a non-monotonic pattern that implicates the escalation schedule [1]. Fatigue reached 43% at 9 mg and 46% on the 6-9 mg escalation against 12% on placebo. The trial describes the drug as generally well tolerated; at those rates that description depends heavily on what participants chose to endure for 20% weight loss, and the abstract does not report discontinuation rates.

Everything else is unknown. No cardiovascular outcome data. No data on lean mass, bone or long-term metabolic adaptation - the last of which matters more for a brainstem-acting satiety drug than for most. Amylin agonism has far less cumulative human exposure than GLP-1 agonism, with pramlintide the main precedent [8].

The class perioperative gastric-emptying precaution should be assumed to apply [10][11].

No interaction studies have been published. The combination the mechanism invites, amylin plus incretin, has been demonstrated for cagrilintide with semaglutide [5] but not for eloralintide with anything. Network meta-analyses comparing the amylin-based agents have begun to appear [7], but these are indirect comparisons, not trials.